Monash spinouts
Monash Innovation supports the translation of University research through the creation of spinout companies turning bold ideas into reality for global economic and social impact. Many of the spinout companies below are currently raising. To learn more about our technology pipelines visit Commercial Opportunities.
2D Water
2D Water is developing graphene-based desalination membranes for water purification.
4D Medical
4D Medical has developed four-dimensional X-ray imaging technology, capturing real time lung motion and airflow in unprecedented detail without invasive procedures.
Acrux
Acrux’s innovative transdermal technology has led to the development and commercialisation of multiple pharmaceuticals, including AXIRON, a spray-on testosterone solution.
Additive Assurance
Additive Assurance provides process monitoring and quality assurance services to the rapidly expanding metal 3D printing industry.
Aravax
Aravax is developing the first safe, convenient and disease-modifying treatment for peanut allergy with lead product PVX108.
Cincera Therapeutics
Cincera Therapeutics is advancing modern approaches to the treatment of fibrotic diseases, developing a novel drug class.
ElectraLith
ElectraLith is enabling lithium to be recovered from solutions as efficiently as possible through the use of direct lithium extraction and refining (DLE-R)
EnyGy
EnyGy has developed patented graphene technology that enables ultracapacitors to achieve up to double the amount of energy density for the same form factor.
Exosome Biosciences
Exosome Biosciences is developing new and novel approaches to treat a range of therapeutic conditions through high-quality exosome isolation.
GILZRx
GILZRx is developing an anti-inflammatory therapeutic small molecule for the treatment of people with inflammatory and autoimmune diseases, including lupus.
GridZync
GridZync's flagship tool, Rezonance, advances impedance-based stability analysis methods to address critical challenges in inverter-dominated power systems.
Inosi
Inosi Therapeutics is developing therapies to address fibrosis, potentially preventing or reversing tissue damage, scarring and a loss of organ function in patients.
Jupiter Ionics
Jupiter Ionics have invented an electrolytic cell that produces green ammonia using only water, air and renewable energy with no CO2 emissions.
KASPR Datahaus
KASPR Datahaus captures real-time information about the world’s internet infrastructure, providing a unique informational advantage to defence and intelligence sectors, humanitarian and disaster relief efforts and more.
Kite Magnetics
Kite Magnetics are developing new materials and technologies for electric motors for small passenger aeroplanes, a range of eVTOLs and electric boats.
Maple Glass
Maple Glass has built the world’s first commercial 3D class printing technology, using glass waste to create bespoke glass products unable to be produced using traditional glass blowing methods.
Mogrify
Mogrify has developed proprietary technologies that can direct cellular reprogramming and the maintenance of cell identity, affecting a direct transdifferentiation from one mature cell type to another.
Monash IVF
Monash IVF research produced the world’s first human IVF pregnancy in 1973 and continues to enable new technologies in reproductive medicine and ultrasound to be delivered to patients as soon as they are available.
MoodMission
MoodMission was designed to deliver evidence-based Cognitive Behaviour Therapy (CBT) strategies in the form of real-time, momentary responses to user-reported low moods and anxiety.
Myostellar
Myostellar is developing novel therapies for the treatment of muscular dystrophies which can stimulate skeletal muscle regeneration with minimal fibrosis.
n0de
n0de is building a cutting-edge digital platform that generates a tailored, dynamic net-zero plan in minutes, allowing an array of businesses to better understand and activate their net-zero transformations more easily.
Opturion
Opturion uses AI and machine learning to simulate organisational processes, empowering businesses to tackle complex problems and optimise efficiency in scheduling, planning, modelling and decision-making.
Orio Therapeutics
Orio Therapeutics have developed technology that modifies therapeutic proteins that controls localisation after injection, improving tissue repair at lower doses while reducing costs and side effects.
Pacalis Therapeutics
Pacalis Therapeutics is pioneering the development of next-generation medicines, targeting serotonin signalling in the brain, which plays a crucial role in mood regulation.
Phrenix
Phrenix Therapeutics is developing new therapeutics for cognitive disorders, particularly in schizophrenia. The current target are GPR52 agonists.
RAGE
RAGE Biotech is developing novel therapies to address the Receptor for Advanced Glycation End-products (RAGE),
Resseptor Therapeutics
Resseptor Therapeutics is developing T-Cell Receptor (TCR) platform technology, engineering therapies for treatment of people with cancer, inflammation and autoimmune disease.
Seaport Therapeutics
Seaport Therapeutics is advancing a clinical stage pipeline of neuropsychiatric medicines in areas of high unmet patient needs including depression and anxiety disorders.
Septerna
Septerna is developing a pipeline of novel small molecule medicines that target GPCRs, providing new drugs or improved alternatives to treat patients with a huge range of diseases.
xCystence
xCystence Bio is developing and optimising new, safe and effective drugs that prevent the formation of new cysts and the growth of existing ones in patients with polycystic kidney disease (PKD).